AtriCure Appoints Scott Drake to Its Board of Directors

  AtriCure Appoints Scott Drake to Its Board of Directors

Business Wire

WEST CHESTER, Ohio -- September 3, 2013

AtriCure, Inc. (NASDAQ: ATRC), a medical device company and a leader in the
development of technologies and solutions for the treatment of atrial
fibrillation, or Afib, and systems for the exclusion of the left atrial
appendage, today announced that Scott Drake, Chief Executive Officer of the
Spectranetics Corporation, has been elected as Director. Donald C. Harrison,
MD, one of the founders of AtriCure, has also informed the Board of Directors
of his plans to retire at the 2013 Annual Meeting in May 2014, following an
orderly transition and after almost 20 years of service with the company.

Mr. Drake is President and Chief Executive Officer of the Spectranetics
Corporation (NASDAQ: SPNC). Spectranetics develops, manufactures, markets and
distributes medical devices used in minimally invasive procedures within the
cardiovascular system. Its products are sold in more than 40 countries and are
used to access and treat arterial blockages in the legs and heart and to
remove pacemaker and defibrillator cardiac leads.Since joining Spectranetics
in August 2011, Mr. Drake has led it through significant growth. Spectranetics
reported $140.3 million in revenue in 2012.

Prior to joining Spectranetics, Mr. Drake was Senior Vice President,
Operations of DaVita, Inc. (NYSE: DVA), a leading U.S. provider of kidney care
and dialysis. At DaVita, he had responsibility for business operations that
generated approximately 20% of the company’s revenue, which exceeded $6
billion. Previously, Mr. Drake held several positions of increasing
responsibility within various healthcare business units at Covidien, Plc over
a period of 17 years. From 2006 to 2009, Mr. Drake was Global Business Unit
President, Respiratory and Monitoring Solutions, a $1.5 billion business with
8,000 employees. Under his leadership, significant operational improvements
were made including revenue and profit growth, enhanced new product
development pipeline, lifting of FDA consent decree and lean six sigma
operational excellence initiatives. Foundational to these accomplishments is
an intense focus on new product development, organizational effectiveness and
customer needs.

“We are thrilled to welcome Scott to our Board of Directors, and look forward
to his contribution to AtriCure. As a seasoned executive, Scott has
significant leadership experience managing growing businesses, achieving
sustainable revenue growth and driving operational improvements. I believe he
will bring meaningful value to AtriCure and to our Board of Directors,” said
Michael Carrel, President and Chief Executive Officer of AtriCure.

“I am pleased to be joining AtriCure’s Board of Directors, and look forward to
contributing to the company’s ongoing success and commercial efforts,” said
Mr. Drake. “AtriCure is at an exciting stage in its development as a company,
and is emerging as a true leader in the field of atrial fibrillation.”

Dr. Don Harrison has also announced that, following an orderly transition and
succession, he will be retiring from the Board of Directors of AtriCure at the
2013 Annual Meeting in May 2014. Dr. Harrison has had an illustrious career
spanning over 50 years. Prior to the founding of Charter Life Sciences, he was
the senior vice president and provost for health affairs at the University of
Cincinnati Medical Center, where he was responsible for three hospitals, more
than 1000 faculty and over $240 million in funded research. Previously, he was
Chief of Cardiology at Stanford University and Co-Director of the Falk
Cardiovascular Research Center at Stanford University. Among his many
professional honors, he has been the president of the American Heart
Association and a trustee of the American College of Cardiology.

“Dr. Harrison was critical to the founding of AtriCure, and his extensive
clinical and scientific expertise in cardiology and knowledge of atrial
fibrillation have been invaluable to AtriCure’s success,” said Mike Carrel,
AtriCure’s President and Chief Executive Officer.

About AtriCure, Inc.

AtriCure, Inc. is a medical device company providing innovative atrial
fibrillation (Afib) solutions designed to produce superior outcomes that
reduce the economic and social burden of atrial fibrillation. AtriCure’s
Synergy Ablation System is the first and only device approved for the
treatment of Persistent and Longstanding Persistent forms of Afib in patients
undergoing certain open concomitant procedures. AtriCure’s AtriClip Left
Atrial Appendage (LAA) exclusion device is the most widely implanted device
for LAA management worldwide.The company believes cardiothoracic surgeons are
adopting its ablation and LAA management devices for the treatment of Afib and
reduction of Afib related complications such as stroke. Afib affects more than
5.5 million people worldwide.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995. Forward-looking
statements include statements that address activities, events or developments
that AtriCure expects, believes or anticipates will or may occur in the
future, such as earnings estimates (including projections and guidance), other
predictions of financial performance, launches by AtriCure of new products and
market acceptance of AtriCure’s products. Forward-looking statements are based
on AtriCure’s experience and perception of current conditions, trends,
expected future developments and other factors it believes are appropriate
under the circumstances and are subject to numerous risks and uncertainties,
many of which are beyond AtriCure’s control. These risks and uncertainties
include the rate and degree of market acceptance of AtriCure’s products,
AtriCure’s ability to develop and market new and enhanced products, the timing
of and ability to obtain and maintain regulatory clearances and approvals for
its products, the timing of and ability to obtain reimbursement of procedures
utilizing AtriCure’s products, competition from existing and new products and
procedures or AtriCure’s ability to effectively react to other risks and
uncertainties described from time to time in AtriCure’s SEC filings, such as
fluctuation of quarterly financial results, reliance on third party
manufacturers and suppliers, litigation or other proceedings, government
regulation and stock price volatility. AtriCure does not guarantee any
forward-looking statement, and actual results may differ materially from those
projected. AtriCure undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information, future
events or otherwise. A further list and description of risks, uncertainties
and other matters can be found in our Annual Reports on Form 10-K and
Quarterly Reports on Form 10-Q.

Contact:

AtriCure, Inc.
Andy Wade, Vice President and Chief Financial Officer, 513-755-4564
awade@atricure.com
OR
Investor Relations
Westwicke Partners
Lynn Pieper, 415-202-5678
lynn.pieper@westwicke.com
 
Press spacebar to pause and continue. Press esc to stop.